Compare GSK plc (GSK) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? GSK plc trades at $52.77 (market cap $101.34B), while Invesco S&P 500 High Div Low Volatility ETF trades at $53.05. The key difference: GSK plc pays a 3.49% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | SPHD | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $52.63 |
52-Week Low | $36.20 | $46.96 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
The Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) trades at $52.91, up 1.79% today, with a bullish technical signal from moving averages. The fund focuses on high-dividend, low-volatility S&P 500 stocks, offering a 4.5% 30-day SEC yield with monthly distributions. Recent news highlights its appeal to retirees seeking reliable income, though performance has trailed the broader S&P 500 historically.
SPHD presents a defensive income opportunity amid market uncertainty, with portfolio shifts toward energy, consumer staples, and financials enhancing resilience. Key risks include underperformance during strong bull markets and interest rate sensitivity. Analyst sentiment is cautiously positive, with Seeking Alpha upgrading to Buy in May 2026 for its defensive positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
